# Biomarkers in Predicting Response to Chemotherapy in Patients With Advanced or Metastatic Melanoma Previously Treated With Carboplatin and Paclitaxel With or Without Sorafenib Tosylate

> **NCT01209299** · — · COMPLETED · sponsor: **ECOG-ACRIN Cancer Research Group** · enrollment: 80 (actual)

## Conditions studied

- Melanoma (Skin)

## Interventions

- **GENETIC:** DNA methylation analysis
- **GENETIC:** gene expression analysis
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT01209299
- **Lead sponsor:** ECOG-ACRIN Cancer Research Group
- **Sponsor class:** NETWORK
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01-19
- **Primary completion:** 2012-02-19
- **Final completion:** 2012-02-19
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2017-05-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01209299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01209299, "Biomarkers in Predicting Response to Chemotherapy in Patients With Advanced or Metastatic Melanoma Previously Treated With Carboplatin and Paclitaxel With or Without Sorafenib Tosylate". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01209299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*